Eliminates tedious cell counting and provides immediate insights into cell health

Millipore Corporation (NYSE: MIL), a leading provider of technologies, tools and services for the global life sciences industry, today introduced Scepter™, the industry’s first handheld, automated cell counter, at the American Society of Cell Biology Annual Meeting in San Diego.

“The Scepter handheld cell counter represents a breakthrough for life science researchers,” said John Sweeney, Vice President of Millipore’s life science business. “Unlike any other cell counter, this handheld device provides researchers with a simple and affordable automated option for counting cells and monitoring the health of their cultures.”

Scepter miniaturizes Coulter cell counting technology found in much larger instruments into a portable device the size of an automated pipette. The instrument contains sophisticated electronics for cell sensing, signal processing, and data storage. A graphical display reports the cell count and average cell volume within 20 seconds of inserting the tip into a cell culture sample.

Currently, cells are typically counted manually under a microscope using a hemocytometer. However, loading a hemocytometer is a tedious task and variability in user technique can impact the accuracy and precision of results. Automated cell counters are available, but these bench top instruments are not portable and are considerably more expensive than the Scepter handheld cell counter.

In addition to showing cell counts and average cell volume, the instrument also displays a histogram of cell distribution by volume or diameter. The histogram can be used to provide an instant snapshot of the health of the culture. Results can be stored on the instrument or downloaded to a computer.

“This introduction once again demonstrates Millipore’s commitment to developing innovative products and technologies that simplify scientific workflows and enable advancements in life science research,” Sweeney added.

The Scepter instrument will be commercially available during the latter half of the first quarter of 2010.

Download High Resolution Image

http://www.millipore.com/press/files/external_press/$file/M9607_091022_115_scepter.jpg

Additional Resources

www.millipore.com/scepter15

About Millipore

Millipore (NYSE: MIL) is a life science leader providing cutting-edge technologies, tools, and services for bioscience research and biopharmaceutical manufacturing. As a strategic partner, we collaborate with customers to confront the world’s challenging human health issues. From research to development to production, our scientific expertise and innovative solutions help customers tackle their most complex problems and achieve their goals. Millipore Corporation is an S&P 500 company with more than 5,900 employees worldwide. For more information, please contact Millipore tech service at 1-800-548-7853 or 951-676-8080 or visit www.millipore.com.

ADVANCING LIFE SCIENCE TOGETHER ®

Research. Development. Production.

Millipore and Advancing Life Science Together are registered trademarks and Scepter and the “M” logo are trademarks of Millipore Corporation.

Safe Harbor Statement

Certain of the matters discussed herein, as well as in future oral and written statements by management of Millipore Corporation that are forward-looking statements, are based on current management expectations that involve substantial risks and uncertainties which could cause actual results to differ materially from the results expressed in, or implied by, these forward-looking statements.

Potential risks and uncertainties that could affect Millipore’s future operating results include, without limitation, failure to achieve new product release targets; failure to achieve design wins into our pharmaceutical and biotechnology customers’ manufacturing design phase for a particular drug or vaccine; delay, suspension or termination of a customer’s volume production; fluctuations in the timing of customers’ orders; lack of availability of raw materials or component products on a timely basis; regulatory delay in the approval of new therapeutics; limitations on cash flow for operations and investment due to debt service obligations; the inability to establish and maintain necessary product and process quality levels; reduced demand for cell culture products using bovine serum; the inability to realize the expected benefits of development, marketing, licensing and other alliances; competitive factors such as new membrane or chromatography technology; risks relating to our concentration of principal manufacturing operations; the inability to successfully integrate acquired businesses; the inability to utilize technology in current or planned products due to overriding rights by third parties; potential environmental liabilities; conditions in the economy in general and in the bioscience and bioprocess markets in particular; foreign exchange fluctuations; reduced private and government research funding; exposure to product liability claims; and difficulties inherent in transferring or outsourcing of manufacturing operations. Please refer to our filings with the SEC, including our most recent Annual Report on Form 10-K, for more information on these and other risks that could cause actual results to differ.